125 Using a scenario approach to assess for the current and future demand of immunoglobulins 103. Krivan G, Jolles S, Lopes Granados E, Paolantonacci P, Cissé O, Bernatowska E. New insights in the use of immunoglobulins for the management of immune deficiency (PID) patients. Am J Clin Exp Immunol. 2017;6(5):76-83. 104. Farrugia A, Grazzini G, Quinti I, Candura F, Profili S, Liumbruno GM. The growing importance of achieving national self-sufficiency in immunoglobulin in Italy. The emergence of a national imperative. Blood Transfus. 2019;17(6):449-458. 105. Reiser M, Borte M, Huscher D, et al. Management of patients with malignancies and secondary immunodeficiencies treated with immu- noglobulins in clinical practice: long-term data of the SIGNS study. Eur J Haematol. 2017;99(2):169-177. 106. Markvardsen LH, Sindrup SH, Christiansen I, et al. Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: random- ized controlled trial study. Eur J Neurol. 2017;24(2):412-418. 107. Langi Sasongko P, van den Hurk K, Van Kraaij M, Rouwette EAJA, Marchau VAWJ, Janssen M. Not a crystal ball: mapping opportuni- ties and threats for the future demand of red blood cells in The Netherlands using a scenario approach. Transfusion. 2021;61:2356- 2367.
RkJQdWJsaXNoZXIy MTk4NDMw